Russia’s Sputnik V vaccine for COVID on 2nd round of evaluation by PH experts — DOST
ADVERTISEMENT

Welcome, Kapamilya! We use cookies to improve your browsing experience. Continuing to use this site means you agree to our use of cookies. Tell me more!
Russia’s Sputnik V vaccine for COVID on 2nd round of evaluation by PH experts — DOST
Kristine Sabillo,
ABS-CBN News
Published Oct 08, 2020 07:42 PM PHT

MANILA — Negotiations with Russia for its possible COVID-19 vaccine has reached a second round of evaluation by local experts, the Philippines' Department of Science said Thursday.
MANILA — Negotiations with Russia for its possible COVID-19 vaccine has reached a second round of evaluation by local experts, the Philippines' Department of Science said Thursday.
“Merong mga kulang na datos na hiningi ang vaccine expert panel. May second round ng evaluation na nangyayari ngayon,” said Dr. Jaime Montoya, Executive Director of DOST-Philippine Council for Health Research and Development, during a Laging Handa briefing.
“Merong mga kulang na datos na hiningi ang vaccine expert panel. May second round ng evaluation na nangyayari ngayon,” said Dr. Jaime Montoya, Executive Director of DOST-Philippine Council for Health Research and Development, during a Laging Handa briefing.
(There are some data that our vaccine expert panel asked for. There is a second round of evaluation happening now.)
(There are some data that our vaccine expert panel asked for. There is a second round of evaluation happening now.)
Montoya said the panel wants to make sure that the vaccine is really safe for Filipinos.
Montoya said the panel wants to make sure that the vaccine is really safe for Filipinos.
ADVERTISEMENT
Besides Russia, he said the Chinese company Sinovac and the European company Janssen are also planning to conduct Phase 3 clinical trials in the Philippines.
Besides Russia, he said the Chinese company Sinovac and the European company Janssen are also planning to conduct Phase 3 clinical trials in the Philippines.
Sinovac already submitted its application during the first week of October, while Janssen is about to complete its documents, Montoya said.
Sinovac already submitted its application during the first week of October, while Janssen is about to complete its documents, Montoya said.
But what the Philippines is prioritizing now is the World Health Organization’s Solidarity Trial, which will involve the simultaneous testing of several COVID-19 vaccines.
But what the Philippines is prioritizing now is the World Health Organization’s Solidarity Trial, which will involve the simultaneous testing of several COVID-19 vaccines.
“Ang simula n'yan, base sa WHO timelines, ay mga last week of this month,” Montoya said, adding that WHO is still finalizing its list of vaccines.
“Ang simula n'yan, base sa WHO timelines, ay mga last week of this month,” Montoya said, adding that WHO is still finalizing its list of vaccines.
(That will start, based on WHO timelines, around the last week of this month.)
(That will start, based on WHO timelines, around the last week of this month.)
ADVERTISEMENT
He said the trials might end “at the earliest, the end of this year, or even early next year.”
He said the trials might end “at the earliest, the end of this year, or even early next year.”
Because of this, he said an approved vaccine won’t be available in the country until the 2nd quarter of next year.
Because of this, he said an approved vaccine won’t be available in the country until the 2nd quarter of next year.
Montoya said the Philippines' participation in the COVAX facility, a global effort that aims to provide for equitable access to new vaccines, would allow the country to receive at least 20% of its demand for vaccines.
Montoya said the Philippines' participation in the COVAX facility, a global effort that aims to provide for equitable access to new vaccines, would allow the country to receive at least 20% of its demand for vaccines.
“Ito po ay 20%. Ito ay lalabas ang supply first quarter next year. With all of our approval sa FDA (Food and Drug Administration) at requirements na kailangan talagang 2nd quarter tayo magkakaroon ng panimulang supply ng bakuna,” he said.
“Ito po ay 20%. Ito ay lalabas ang supply first quarter next year. With all of our approval sa FDA (Food and Drug Administration) at requirements na kailangan talagang 2nd quarter tayo magkakaroon ng panimulang supply ng bakuna,” he said.
(This is 20%. It will come out in the first quarter next year. With all of our approval requirements from the FDA and others, we expect the initial supply to arrive during the 2nd quarter.)
(This is 20%. It will come out in the first quarter next year. With all of our approval requirements from the FDA and others, we expect the initial supply to arrive during the 2nd quarter.)
ADVERTISEMENT
He said that the initial allocation will be given to health care workers (3%) and members of the vulnerable population (17%) such as those who are old or have existing medical conditions.
He said that the initial allocation will be given to health care workers (3%) and members of the vulnerable population (17%) such as those who are old or have existing medical conditions.
He said the remaining 80% of vaccines needed by the Philippines will still undergo negotiations as well.
He said the remaining 80% of vaccines needed by the Philippines will still undergo negotiations as well.
The Philippines has recorded, as of Thursday, a total of 331,869 confirmed COVID-19 cases, of which, 6,069 resulted in deaths.
The Philippines has recorded, as of Thursday, a total of 331,869 confirmed COVID-19 cases, of which, 6,069 resulted in deaths.
The country's first case was confirmed on Jan. 30 in a Chinese woman who arrived from Wuhan City, China where the disease is believed to have first emerged.
The country's first case was confirmed on Jan. 30 in a Chinese woman who arrived from Wuhan City, China where the disease is believed to have first emerged.
Read More:
COVID-19
coronavirus
DOH
Department of Health
COVID-19 clinical trials
clinical trials
Solidarity Trial
World Health Organization
COVID-19 vaccine
Sputnik V
ADVERTISEMENT
ADVERTISEMENT